Skinvisible (SKVI) EBITDA Margin (2010 - 2026)

Skinvisible has disclosed EBITDA Margin across 17 years of filings, most recently posting 2256.34% for Q2 2026.

• In Q2 2026, EBITDA Margin rose 46840.0% year-over-year to 2256.34%; the TTM figure through Jun 2026 stood at 2294.91% (up 70410.0% YoY), while the FY2025 annual figure was 2481.57%, up 46637.0% from the prior year.
• EBITDA Margin came in at 2256.34% for Q2 2026 at Skinvisible, up from 2518.76% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 41.95% in Q2 2022 to a low of 3974.86% in Q4 2024.
• Average EBITDA Margin over 5 years is 2228.37%, with a median of 2409.0% recorded in 2022.
• Year-over-year, EBITDA Margin tumbled 242547 bps in 2023 and soared 169148 bps in 2025.
• Over 5 years, EBITDA Margin stood at 2354.32% in 2022, then retreated by 16 bps to 2730.76% in 2023, then plunged by 46 bps to 3974.86% in 2024, then soared by 43 bps to 2283.38% in 2025, then advanced by 1 bps to 2256.34% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 2256.34% in Q2 2026, 2518.76% in Q1 2026, and 2283.38% in Q4 2025.